Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy

International Journal of Urology

Volumn 13, Issue 8, 2006, Pages 1123-1125

  Kojima, Yoshiyuki ^a   Yamada, Yasuyuki ^a   Kamisawa, Hideyuki ^a   Sasaki, Shoichi ^a   Hayashi, Yutaro ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Bladder neoplasm; Chemotherapy; Neoplasm metastasis; Urachus

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CYSTECTOMY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; INTERNAL ILIAC ARTERY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NEUTROPENIA; PELVIS LYMPH NODE; PRIORITY JOURNAL; URACHUS;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; HEMATURIA; HUMANS; ILIAC ARTERY; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; OXONIC ACID; TEGAFUR; URACHUS; URINARY BLADDER NEOPLASMS;

EID: 33746447942     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01487.x     Document Type: Article

References (10)

1. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990; 50: 197-201.
2. Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-57.
3. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993; 53: 4004-9.
4. Henly DR, Farrow GM, Zincke H. Urachal cancer: role of conservative surgery. Urology 1993; 42: 635-9.
5. Siefker-Radtke AO, Gee J, Shen Y et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J. Urol. 2003; 169: 1295-8.
6. Sugimachi K, Maehara Y, Horikoshi N et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 1999; 57: 202-10.
7. Iwase H, Indo T, Shimada M et al. Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin. Int. J. Clin. Oncol. 2004; 9: 398-402.
8. Yoshimizu N, Saikawa Y, Kubota T et al. Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin. Gastric Cancer 2003; 6: 185-90.
9. Ichinose Y, Yoshimori K, Sakai H et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin. Cancer Res. 2004; 10: 7860-4.
10. Iwahashi M, Nakamori M, Tani M et al. Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case. Oncology 2001; 61: 16-22.